Literature DB >> 9480911

Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.

A P Koval1, V A Blakesley, C T Roberts, Y Zick, D Leroith.   

Abstract

The Crk proto-oncogene product is an SH2 and SH3 domain-containing adaptor protein. We have previously demonstrated that Crk-II becomes rapidly tyrosine-phosphorylated in response to stimulation with insulin-like growth factor I (IGF-I) and might be involved in the IGF-I receptor signalling pathway. To determine whether this involvement includes the direct interaction of Crk-II with the cytoplasmic region of the receptor, studies were performed in vitro with glutathione S-transferase (GST) fusion proteins containing various domains of Crk-II. The kinase assay in vitro showed that activated IGF-I receptors efficiently phosphorylated the GST-Crk-II fusion protein. This phosphorylation was dependent on the presence of the SH2 domain and Tyr-221 located in the spacer region between the two SH3 domains. Mutation of Tyr-221 not only prevented phosphorylation of GST-Crk in vitro, but also significantly increased the ability of GST-Crk proteins to co-precipitate activated IGF-I receptors from total cell lysates. Additional binding experiments in vitro showed that Crk-II might interact with the phosphorylated IGF-I receptor through its SH2 domain. To elucidate which region of the IGF-I receptor interacts with Crk-II, a peptide association assay was used in vitro. Different domains of the IGF-I receptor were expressed as (His)6-tagged fusion peptides, phosphorylated with activated wheat germ agglutinin-purified IGF-I receptors and tested for association with GST-Crk-II fusion proteins. Using wild-type as well as mutated peptides, we showed that the SH2 domain of Crk-II preferentially binds the peptide encoding the juxtamembrane region of the IGF-I receptor. Phosphorylation of Tyr-950 and Tyr-943 of the receptor is important for this interaction. These findings allow us to propose a model of direct interaction of Crk-II and the IGF-I receptor in vivo. On activation of the IGF-I receptor, Crk-II binds to phosphorylated tyrosine residues, especially in the juxtamembrane region. As a result of this binding, the IGF-I receptor kinase phosphorylates Tyr-221 of Crk-II, resulting in a change in intramolecular folding and binding of the SH2 domain to the phosphorylated Tyr-221, which causes rapid disassociation of the Crk-II-IGF-I receptor complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9480911      PMCID: PMC1219226          DOI: 10.1042/bj3300923

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

1.  The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Authors:  Y Ebina; L Ellis; K Jarnagin; M Edery; L Graf; E Clauser; J H Ou; F Masiarz; Y W Kan; I D Goldfine
Journal:  Cell       Date:  1985-04       Impact factor: 41.582

2.  Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G.

Authors:  K A Reedquist; T Fukazawa; G Panchamoorthy; W Y Langdon; S E Shoelson; B J Druker; H Band
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

3.  Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts.

Authors:  R B Birge; J E Fajardo; C Reichman; S E Shoelson; Z Songyang; L C Cantley; H Hanafusa
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

4.  Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor.

Authors:  E P Feener; J M Backer; G L King; P A Wilden; X J Sun; C R Kahn; M F White
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

5.  The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids.

Authors:  B Zhang; J M Tavaré; L Ellis; R A Roth
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

6.  The role of insulin receptor kinase domain autophosphorylation in receptor-mediated activities. Analysis with insulin and anti-receptor antibodies.

Authors:  P A Wilden; K Siddle; E Haring; J M Backer; M F White; C R Kahn
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

7.  Mutation of a conserved amino acid residue (tryptophan 1173) in the tyrosine kinase domain of the IGF-I receptor abolishes autophosphorylation but does not eliminate biologic function.

Authors:  V A Blakesley; H Kato; C T Roberts; D LeRoith
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

8.  Insulin-like growth factor I receptors in neuronal and glial cells. Characterization and biological effects in primary culture.

Authors:  J Shemer; M K Raizada; B A Masters; A Ota; D LeRoith
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

Review 9.  Insulin action and the insulin signaling network.

Authors:  B Cheatham; C R Kahn
Journal:  Endocr Rev       Date:  1995-04       Impact factor: 19.871

10.  CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.

Authors:  R Salgia; N Uemura; K Okuda; J L Li; E Pisick; M Sattler; R de Jong; B Druker; N Heisterkamp; L B Chen
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

View more
  8 in total

1.  Regulation of Id gene expression by type I insulin-like growth factor: roles of Stat3 and the tyrosine 950 residue of the receptor.

Authors:  M Prisco; F Peruzzi; B Belletti; R Baserga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

3.  Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

4.  IGF and insulin receptor signaling in breast cancer.

Authors:  Antonino Belfiore; Francesco Frasca
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-19       Impact factor: 2.673

5.  Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances.

Authors:  Kenneth Siddle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-28       Impact factor: 5.555

6.  Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells.

Authors:  Pooja Dhupkar; Huang Zhao; Kalpana Mujoo; Zhiqiang An; Ningyan Zhang
Journal:  Biochem Biophys Rep       Date:  2016-10-28

7.  Research on Quality Evaluation of Product Interactive Aging Design Based on Kano Model.

Authors:  Yin Liu; Weiwei Wang
Journal:  Comput Intell Neurosci       Date:  2022-01-31

Review 8.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.